-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| Sector | Healthcare |
| Industry | Biotechnology |
| ISIN | US20678X2053 |
| Beta | 2.35 |
|---|---|
| Market Cap | None |
| PE Ratio | None |
| Target Price | None |
| Dividend Yield | None |
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in Naples, Florida.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CDTTW using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025